Literature DB >> 15113589

The G2028R glycine substitution mutation in COL7A1 leads to marked inter-familiar clinical heterogeneity in dominant dystrophic epidermolysis bullosa.

Hiroyuki Nakamura1, Daisuke Sawamura, Maki Goto, Kazuko C Sato-Matsumura, Jeffrey LaDuca, Julia Yu-Yun Lee, Takuji Masunaga, Hiroshi Shimizu.   

Abstract

BACKGROUND: Glycine substitution mutations in COL7A1 not only cause dominant dystrophic epidermolysis bullosa (DDEB), but can also be silent mutations which lead to recessive dystrophic epidermolysis bullosa (RDEB) in combination with additional mutations in the other allele.
OBJECTIVE: In this study, we have examined a large American Caucasian pedigree in which 10 family members from four generations presented with simple toenail dystrophy without skin fragility in autosomal dominant manner.
METHOD: We sequenced COL7A1 of this pedigree.
RESULTS: Mutational analysis indeed detected a heterozygous G-to-A transition at nucleotide position 6082 leading to G2028R in all the affected members. Surprisingly, mutation database revealed that this G2028R mutation had been previously identified in two distinct Asian families with DDEB showing apparent skin fragility and blister formation. One case was a 17-month-old Chinese female with classical phenotype of DDEB and the other was a 27-year-old Japanese female with typical epidermolysis bullosa (EB) pruriginosa. To better understand the molecular mechanisms of this marked inter-familiar clinical heterogeneity, we examined the entire sequence of all the exons and exon-intron borders as well as the promoter region of COL7A1 in all the three families. Sequence results demonstrated no significant nucleotide difference in COL7A1 among the three pedigrees.
CONCLUSION: This paper has demonstrated for the first time that identical COL7A1 glycine substitutions can cause remarkably heterogeneous clinical phenotypes extending from simple toe nail dystrophy without skin fragility to typical DDEB and EB pruriginosa. In addition, the fact of inter-familiar, not intra-familiar clinical heterogeneity associated with G2028R suggest that the other molecular mechanisms not controlled by COL7A1 coding sequence might be responsible for the clinical heterogeneity. Copyright 2004 Japanese Society for Investigative Dermatology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113589     DOI: 10.1016/j.jdermsci.2004.02.005

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  5 in total

1.  Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes.

Authors:  Roslyn Varki; Sara Sadowski; Jouni Uitto; Ellen Pfendner
Journal:  J Med Genet       Date:  2006-09-13       Impact factor: 6.318

2.  A novel COL7A1 gene mutation in an Iranian individual suffering dystrophic epidermolysis bullosa.

Authors:  Hamid Galehdari; Gholamreza Mohammadian; Somayeh Azmoon; Bahaoddin Salehi; Mohammad Pedram
Journal:  J Mol Diagn       Date:  2010-02-26       Impact factor: 5.568

3.  An incompletely penetrant novel mutation in COL7A1 causes epidermolysis bullosa pruriginosa and dominant dystrophic epidermolysis bullosa phenotypes in an extended kindred.

Authors:  Catherine S Yang; Yin Lu; Anita Farhi; Carol Nelson-Williams; Michael Kashgarian; Earl J Glusac; Richard P Lifton; Richard J Antaya; Keith A Choate
Journal:  Pediatr Dermatol       Date:  2012-04-20       Impact factor: 1.588

Review 4.  Epidermolysis Bullosa-A Different Genetic Approach in Correlation with Genetic Heterogeneity.

Authors:  Monica-Cristina Pânzaru; Lavinia Caba; Laura Florea; Elena Emanuela Braha; Eusebiu Vlad Gorduza
Journal:  Diagnostics (Basel)       Date:  2022-05-27

5.  Scanning electron microscopy of a blister roof in dystrophic epidermolysis bullosa.

Authors:  Hiram Larangeira de Almeida; Luciane Monteiro; Ricardo Marques e Silva; Nara Moreira Rocha; Hans Scheffer
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.